Major pharmaceutical companies tend to nanotechnology

Day after day, more and more pharmaceutical companies are moving to the use of nanotechnology, it believes these major companies, the demand for this technology will be an important event in the future.


And provides the ability to develop effective drugs in micro-capsules measured diameter portions of a billionth of a meter, new options in order to achieve the greatest benefit from the property, and increase the accuracy of targeting the site of the disease, which the researchers hope to reduce the side effects of drugs.

The company entered into Baand Tirabaotks three agreements this year with a total value of about one billion dollars, if successful experiments, which highlights the new interest in using such a small capsules to transport the drug to specific sites in the body.

And Baand company, based in the United States, is one of several companies specializing in biotechnology that will attract major pharmaceutical companies a range of smart nano-technology on the drugs, especially for the fight against cancer.


And nano-technology is also used in the diagnosis, where the employment of ultrafine particles in improving imaging devices and scanning speed detection serious types of infections.

In the future, the researchers hope to combine the treatment and diagnosis in a new approach, called "Threnostics", allows doctors follow their patients through medication.


After the bustle of a large owner scientific success is limited, the researchers in the nanotechnology sector finally turning point. Dan said Bear, who runs a laboratory nano-medicine at the University of Tel Aviv: "We hear about the virtues of nanotechnology a long time ago, but he already began to move now."

He added: "There is a new level of confidence in this approach among major pharmaceutical companies.'ll See more products in the framework of the tests over the next few years, and I think that's very exciting."

The nanoparticles are made ​​of polymers and gold, as well as graphene - a new form of carbon discovered recently - which is currently in various stages of development.


With regard to cancer alone is currently being evaluated about 117 properties using combinations of nano-particles, although most of them have not been tested in practice on patients, according to data from Thomson Reuters Pharma.

Said Robert Langer, one of the pioneers of medicine nanotechnology, which runs the largest plant engineering Biomedical in the world at the Massachusetts Institute of Technology: "All these developments prompted companies to look for new ways, because the ways older to use the drugs did not work very well."